Bluejay Diagnostics (NASDAQ: BJDX) details 2026 plan and finances
Rhea-AI Filing Summary
Bluejay Diagnostics, Inc. filed a current report after issuing a press release that outlines its 2026 strategic outlook and recent progress. The company continues advancing its Symphony platform and SYMON II clinical study for an Interleukin-6 test to support sepsis risk assessment, with enrollment and site activity proceeding as planned for regulatory purposes.
Bluejay reports ongoing manufacturing scale-up, supply-chain work, and process validation to prepare for potential commercialization. During February 2026, previously issued prefunded warrants were fully exercised and converted into common shares, leaving approximately 972,000 common shares outstanding plus cash-exercisable warrants with strike prices above current trading levels.
The company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, after a $3.8 million warrant-inducement financing in April 2025 and a $4.5 million PIPE in October 2025. Net loss for 2025 was about $6.8 million. Management states that 2026 priorities center on clinical validation, manufacturing readiness, and positioning the Symphony platform for future regulatory submission and commercialization.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol (s) | Name of each exchange on which registered | ||
| The |
| Item 2.02 | Results of Operations and Financial Condition. |
On March 6, 2026, Bluejay Diagnostics, Inc. (the “Company”) issued a press release providing a corporate and strategic update, as well as certain financial results as of and for the year ended December 31, 2025. A copy of that press release is furnished with this report as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 99.1 |
Press release, dated March 6, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Bluejay Diagnostics, Inc. | |||
| By: | /s/ Neil Dey | ||
| Neil Dey | |||
| President and Chief Executive Officer | |||
| Date: March 6, 2026 | |||
Exhibit 99.1
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook
ACTON, Mass., March 6, 2026 — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026.
Operational and Clinical Progress
Bluejay continues to advance its Symphony™ platform, including the Company’s lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making.
The Company confirmed that its SYMON™ II clinical study is progressing as planned, with ongoing site activities and enrollment consistent with internal timelines. Data generated from this study is intended to support the Company’s regulatory strategy. Due to regulatory considerations, including FDA requirements and disclosure constraints, Bluejay may be limited in its ability to release detailed clinical data prior to regulatory submission; however, the Company intends to provide appropriate updates in accordance with the analysis of primary end points with the study’s statistical analysis plan.
Manufacturing and Commercial Readiness
Bluejay continues to execute its manufacturing readiness strategy, including scale-up activities designed to support both clinical and future commercial production. Key supply-chain initiatives and process validation efforts remain on track, positioning the Company for planned regulatory submission and subsequent commercialization readiness.
The Company has achieved meaningful progress in critical raw materials, antibody supply, cartridge manufacturing preparation, and external manufacturing coordination, which collectively reduce historical supply-chain risk and support long-term scalability.
Corporate and Capital Structure Update
During February 2026, the Company announced the full exercise of previously issued prefunded warrants. These exercises represented the conversion of existing instruments into common shares and did not create incremental dilution beyond the Company’s previously disclosed fully diluted share structure.
Following these exercises, the Company has approximately 972,000 shares of common stock outstanding, in addition to outstanding cash-exercisable warrants with strike prices above current trading levels.
The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.
2026 Strategic Priorities
Through 2026, Bluejay’s primary strategic focus areas include:
| · | Completion and execution of the SYMON™ II study and advancement toward regulatory submission |
| · | Continued manufacturing scale-up and operational readiness for commercialization |
| · | Strengthening supply-chain robustness and production capacity |
| · | Advancement of Symphony™ platform capabilities |
| · | Ongoing engagement with investors, scientific conferences, and strategic partners |
| · | Raising additional capital as part of the Company’s expectation that it will need to raise at least $20 million of further capital through the end of the 2027 fiscal year, which it hopes to do in various tranches. |
The Company expects to provide updates through press releases, conference participation, and other investor communications as milestones are achieved or material developments occur.
Management Commentary
“Bluejay continues to execute against its core clinical, operational, and regulatory priorities,” said Neil Dey, Chief Executive Officer of Bluejay Diagnostics. “Our focus through 2026 remains disciplined — advancing clinical validation, preparing manufacturing for commercialization, and positioning the Symphony platform to deliver meaningful value for patients, clinicians, and shareholders.”
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com
FAQ
What strategic update did Bluejay Diagnostics (BJDX) provide for 2026?
How is Bluejay Diagnostics’ SYMON II clinical study progressing?
What is Bluejay Diagnostics’ cash and equity position as of December 31, 2025?
How many Bluejay Diagnostics shares are outstanding after warrant exercises?
What were Bluejay Diagnostics’ 2025 financial results mentioned in the update?
What is the focus of Bluejay Diagnostics’ Symphony IL-6 test?
Filing Exhibits & Attachments
4 documents